A key event in chronic allergic
asthma is the TGF-β-induced activation of fibroblasts into α-SMA-positive myofibroblasts which synthesize
type-I collagen. In the present study we investigated the effect of the anti-fibrotic molecule
BMP-7 in
asthma. Balb/c mice were immunized i.p. with
ovalbumin in
alum and challenged every 2 days with
ovalbumin aerosol (two or six challenges for acute and chronic protocols, respectively). The lung was evaluated for: α-SMA and
type-I collagen by immunohistochemistry;
BMP-7 and TGF- β1 gene expression by qRT-PCR;
type-I collagen and Smads 2 and 3 by immunoblotting; mucus by PSA staining.
Type-I collagen around bronchi, α-SMA, mucus secretion, TGF- β1 and
BMP-7 gene expression were all increased in
asthma. The TGF- β1/BMP-7 ratio was higher in the chronic group and correlated with higher levels of
collagen. Fibroblasts isolated from asthmatic and healthy lungs produced
type-I collagen upon stimulation with TGF- β1 via phosphorylation of Smad-2, Smad-3. Pre-treatment of the fibroblasts with
BMP-7 reduced
collagen production and Smads phosphorylation. Intranasal treatment of asthmatic mice with recombinant
BMP-7 during the immunization protocol reduced
lung inflammation and
type I collagen deposition. These results suggest a protective role for
BMP-7 in lung allergic
inflammation, opposing the pro-fibrotic effects of TGF- β1.